
The VISTA clinical trial is for male patients ages 13 to 50 years (inclusive) diagnosed with X-linked retinitis pigmentosa (XLRP), a rare form of RP that causes progressive vision loss. If a patient meets the eligibility criteria, he may be randomly assigned to one of two “treatment” groups – either the lower-dose treatment group, the higher-dose treatment group, or a third “untreated control group.”
Refer a patient for pre-screening Learn more about pre-screening